QTY

Avalon GloboCare Announces Notice of Publication for Key U.S. Patent Filed Jointly with the Massachusetts Institute of Technology (MIT)

Retrieved on: 
Dienstag, September 5, 2023
Avalon, Patent, COVID-19, MIT, Solubility, Internet, CAR, Protein, QTY, Cancer, Massachusetts Institute of Technology, Vaccine

FREEHOLD, N.J., Sept. 05, 2023 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. (“Avalon” or the “Company”) (NASDAQ: ALBT), a developer of innovative precision diagnostics and provider of clinical laboratory services, today announced that the United States Patent and Trademark Office (USPTO) has issued a Notice of Publication for U.S. Patent No.

Key Points: 
  • FREEHOLD, N.J., Sept. 05, 2023 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. (“Avalon” or the “Company”) (NASDAQ: ALBT), a developer of innovative precision diagnostics and provider of clinical laboratory services, today announced that the United States Patent and Trademark Office (USPTO) has issued a Notice of Publication for U.S. Patent No.
  • 11,555,060, titled “QTY Fc Fusion Water Soluble Receptor Proteins.” The publication may be accessed through the USPTO’s publicly available Searchable Databases via the Internet at www.uspto.gov .
  • The patent covers the composition of matter and methodology for multiple novel QTY-Code modified cytokine and chemokine protein receptor molecules.
  • The patent was jointly filed with Dr. Shuguang Zhang of the Massachusetts Institute of Technology (MIT).

Avalon GloboCare Provides Update on New Commercial Strategy

Retrieved on: 
Montag, Juli 10, 2023
Insurance, Exhibition, Diabetes, Principal investigator, Genetic testing, Research, MIT, National Health Laboratory Service, LSM, Acquisition, QTY, Laboratory, European, Toxicology, AI, Cytokine, R, Massachusetts Institute of Technology, D, Pharmaceutical industry

FREEHOLD, N.J., July 10, 2023 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. (“Avalon” or the “Company”) (NASDAQ: ALBT), a developer of innovative precision diagnostics and provider of clinical laboratory services, today provided the following letter to shareholders from the Company’s President and CEO, David Jin, M.D., Ph.D.:

Key Points: 
  • Avalon is dedicated to developing and delivering innovative, transformative, precision diagnostics and clinical laboratory services.
  • Our evolving strategy involves acquiring ownership or license rights to precision diagnostic assets, genetic testing and clinical laboratory companies through joint ventures, share ownership structures or distribution rights.
  • We intend to play a leading role in the innovation of diagnostic testing, utilizing proprietary technology to deliver precise, genetics-driven results.
  • In turn, we believe our profit-sharing arrangement with LSM will result in significant future cash flow to Avalon.